About seaport therapeutics inc - SPTX
Seaport Therapeutics, Inc. is a clinical-stage therapeutics company, which engages in the provision of inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company was founded on April 1, 2024 and is headquartered in Boston, MA.
SPTX At a Glance
Seaport Therapeutics, Inc.
101 Seaport Boulevard
Boston, Massachusetts 02210
| Phone | 1-617-807-4062 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -74,881,000.00 | |
| Sector | Health Technology | Employees | 54 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SPTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
SPTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,386,685.185 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SPTX Liquidity
| Current Ratio | 17.464 |
| Quick Ratio | 17.464 |
| Cash Ratio | 16.897 |
SPTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -26.517 |
| Return on Equity | -28.084 |
| Return on Total Capital | -31.481 |
| Return on Invested Capital | -27.69 |
SPTX Capital Structure
| Total Debt to Total Equity | 2.183 |
| Total Debt to Total Capital | 2.136 |
| Total Debt to Total Assets | 2.04 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 1.448 |